USP Workshops Address Variety of Pharma Issues

Article

The US Pharmacopeial Convention is hosting a variety of workshops in Autumn 2017 on a wide range of topics including continuing education, bioassays, and peptides.

The US Pharmacopeial Convention (USP) will be hosting five workshops in the fall of 2017 that will address current scientific findings, regulatory trends, and public health issues. The workshops are open to anyone interested, and more information can be found on USP’s website.

The following workshops are available:

  • Re-thinking Pharmaceutical Technology Continuing Education, Sept. 14–15, 2017. This workshop, cosponsored by the National Institute for Pharmaceutical Technology and Education (NIPTE), will include presentations on NIPTE training programs and USP’s standardization and educational programs. Topics discussed will include pharmaceutical continuing education and education best practices.

  • USP’s 7th Bioassay Workshop–Bioassay: A Lifecycle Approach, Sept. 25–26, 2017. This workshop will take a look at how lifecycle and QbD perspectives are being incorporated into bioassays. Lifecycle methods from scientific, statistical, and regulatory perspectives will be discussed. 

  • Computer Modeling–In-vitro and In-vivo Studies, Oct. 23–25, 2017. This workshop will address how computer modeling and simulation can be useful tools to accelerate product development.

  • IPA Probiotic Workshop in DC, Oct. 26, 2017. Cosponsored by the International Probiotics Association, this workshop will foster open dialogue on how probiotics may be considered within regulations.

  • 4th USP Workshop on Synthetic Therapeutic Peptides: Regulations, Standards and Quality, Nov. 6­–7, 2017. Attendees will learn about USP’s standards and regulatory expectations for peptide products. Strategies for control of raw materials and impurities will be discussed.

Visit www.usp.org for more information.

Source: USP

Recent Videos
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Related Content